News Novartis’ Mayzent EU approval offers SPMS patients new option Richard Staines multiple sclerosis, neurology, Novartis, SPMS 0 Comment Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share X Novartis’ Mayzent EU approval offers SPMS patients new option https://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
